View Post

U.S. FDA Reviews Heart Health Risks from mRNA Vaccine

In COVID-19, Latest News by Precision Vaccinations

Massachusetts based Moderna, Inc. provided an update on October 31, 2021, that the U.S. Food and Drug Administration (FDA) had notified the Company that it would require additional time to complete its assessment of Moderna’s recent Emergency Use Authorization (EUA) request.
The new EUA request is for the use of the Moderna COVID-19 vaccine (mRNA-1273) at the 100 µg dose level in adolescents 12 to 17 years of age.

View Post

Access to COVID-19 Vaccines Found More Relevant than Which Vaccine

In COVID-19, Latest News by Precision Vaccinations

Most high-income countries have secured an abundant supply of COVID-19 vaccines. However, to these researchers’ knowledge, there is no assessment of the pragmatic effectiveness of the COVID-19 vaccines used in low- and moderate-income countries.
Published by the JAMA Network on October 29, 2021, researchers conducted an Original Investigation that found a pragmatic implementation of a group of COVID-19 vaccines was associated with a dramatic reduction in documented COVID-19 infection.